No Data
Bailong Chuangyuan (605016.SH): At this stage, the company's allulose products have no sales to the end consumer.
On April 21, Gelonghui reported that Bailong Chuangyuan (605016.SH) stated on the investor interaction platform that the new production capacity for allulose has officially started production in May 2024 and is currently in normal production status; at this stage, there are no C-end sales for the company's allulose products. All information from the company is subject to the announcements made in designated media.
Investors Continue Waiting On Sidelines For Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHSE:605016)
Bailong Chuangyuan: Earnings Forecast Announcement for the First Quarter of 2025
2025 First Quarter Results Forecast Announcement
Bailong Chuangyuan (605016.SH): Expected net income growth of 49.41% to 58.75% year-on-year in the first quarter.
On April 9, Gelonghui announced that Bailong Chuangyuan (605016.SH) released its performance forecast for the first quarter of 2025. The net income attributable to shareholders of the listed company is expected to increase by 26.4568 million yuan to -31.4568 million yuan compared to the same period last year, representing a year-on-year growth of 49.41% to 58.75%. After deducting non-recurring gains and losses, the net income attributable to shareholders of the listed company is expected to increase by 29.0636 million yuan to -34.0636 million yuan compared to the same period last year, which is an increase of 56.71% to 66.47% year-on-year.
Do Shandong Bailong Chuangyuan Bio-Tech's (SHSE:605016) Earnings Warrant Your Attention?
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHSE:605016) Not Flying Under The Radar
